KR102430453B1 - C1 에스터라제 억제제 결핍과 관련된 장애의 예방 및 치료를 위한 c1-inh 조성물 및 방법 - Google Patents

C1 에스터라제 억제제 결핍과 관련된 장애의 예방 및 치료를 위한 c1-inh 조성물 및 방법 Download PDF

Info

Publication number
KR102430453B1
KR102430453B1 KR1020217033628A KR20217033628A KR102430453B1 KR 102430453 B1 KR102430453 B1 KR 102430453B1 KR 1020217033628 A KR1020217033628 A KR 1020217033628A KR 20217033628 A KR20217033628 A KR 20217033628A KR 102430453 B1 KR102430453 B1 KR 102430453B1
Authority
KR
South Korea
Prior art keywords
composition
esterase
esterase inhibitor
units
hae
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217033628A
Other languages
English (en)
Korean (ko)
Other versions
KR20210129267A (ko
Inventor
신시아 갤러거
스티븐 루디
마르크 콘넬 매닝
Original Assignee
바이로파마 바이오로직스 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51538486&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102430453(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 바이로파마 바이오로직스 엘엘씨 filed Critical 바이로파마 바이오로직스 엘엘씨
Publication of KR20210129267A publication Critical patent/KR20210129267A/ko
Application granted granted Critical
Publication of KR102430453B1 publication Critical patent/KR102430453B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
KR1020217033628A 2013-03-15 2014-03-17 C1 에스터라제 억제제 결핍과 관련된 장애의 예방 및 치료를 위한 c1-inh 조성물 및 방법 Active KR102430453B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361791399P 2013-03-15 2013-03-15
US61/791,399 2013-03-15
PCT/US2014/030309 WO2014145519A2 (en) 2013-03-15 2014-03-17 C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency
KR1020157022897A KR20150135242A (ko) 2013-03-15 2014-03-17 C1 에스터라제 억제제 결핍과 관련된 장애의 예방 및 치료를 위한 c1-inh 조성물 및 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020157022897A Division KR20150135242A (ko) 2013-03-15 2014-03-17 C1 에스터라제 억제제 결핍과 관련된 장애의 예방 및 치료를 위한 c1-inh 조성물 및 방법

Publications (2)

Publication Number Publication Date
KR20210129267A KR20210129267A (ko) 2021-10-27
KR102430453B1 true KR102430453B1 (ko) 2022-08-05

Family

ID=51538486

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020217033628A Active KR102430453B1 (ko) 2013-03-15 2014-03-17 C1 에스터라제 억제제 결핍과 관련된 장애의 예방 및 치료를 위한 c1-inh 조성물 및 방법
KR1020157022897A Ceased KR20150135242A (ko) 2013-03-15 2014-03-17 C1 에스터라제 억제제 결핍과 관련된 장애의 예방 및 치료를 위한 c1-inh 조성물 및 방법
KR1020217004777A Ceased KR20210021146A (ko) 2013-03-15 2014-03-17 C1 에스터라제 억제제 결핍과 관련된 장애의 예방 및 치료를 위한 c1-inh 조성물 및 방법
KR1020227016244A Active KR102579789B1 (ko) 2013-03-15 2014-03-17 C1 에스터라제 억제제 결핍과 관련된 장애의 예방 및 치료를 위한 c1-inh 조성물 및 방법

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020157022897A Ceased KR20150135242A (ko) 2013-03-15 2014-03-17 C1 에스터라제 억제제 결핍과 관련된 장애의 예방 및 치료를 위한 c1-inh 조성물 및 방법
KR1020217004777A Ceased KR20210021146A (ko) 2013-03-15 2014-03-17 C1 에스터라제 억제제 결핍과 관련된 장애의 예방 및 치료를 위한 c1-inh 조성물 및 방법
KR1020227016244A Active KR102579789B1 (ko) 2013-03-15 2014-03-17 C1 에스터라제 억제제 결핍과 관련된 장애의 예방 및 치료를 위한 c1-inh 조성물 및 방법

Country Status (30)

Country Link
US (9) US9616111B2 (https=)
EP (3) EP3290046B1 (https=)
JP (9) JP6184581B2 (https=)
KR (4) KR102430453B1 (https=)
CN (2) CN111529708A (https=)
AU (3) AU2014232912A1 (https=)
BR (1) BR112015023207A8 (https=)
CA (2) CA3054718A1 (https=)
CY (2) CY1119419T1 (https=)
DE (1) DE202014011208U1 (https=)
DK (2) DK2968434T3 (https=)
EA (1) EA201591278A1 (https=)
ES (2) ES2639833T3 (https=)
GB (1) GB2530921B (https=)
HK (1) HK1250912B (https=)
HR (2) HRP20171269T1 (https=)
HU (2) HUE036224T2 (https=)
IL (2) IL241549B (https=)
LT (2) LT3290046T (https=)
ME (2) ME03326B (https=)
MX (3) MX373965B (https=)
PL (2) PL3290046T3 (https=)
PT (2) PT2968434T (https=)
RS (2) RS58351B1 (https=)
SG (2) SG10201707598QA (https=)
SI (2) SI2968434T1 (https=)
SM (2) SMT201900141T1 (https=)
TR (1) TR201900319T4 (https=)
WO (1) WO2014145519A2 (https=)
ZA (3) ZA201507604B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015023207A8 (pt) 2013-03-15 2018-01-23 Shire Viropharma Inc composições de ci-inh e métodos para prevenção e tratamento de desordens associadas à deficiência de inibidor de c1 esterase.
NZ719724A (en) * 2013-11-22 2022-08-26 Takeda Pharmaceuticals Co Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor
JP6516855B2 (ja) * 2015-02-20 2019-05-22 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー Ｃ１エステラーゼ阻害剤の医薬製剤
HK1250623A1 (zh) * 2015-05-28 2019-01-11 Cornell University 腺相关病毒介导的c1ei递送作为用於血管性水肿的疗法
CA3005906A1 (en) * 2015-11-19 2017-05-26 Shire Human Genetic Therapies, Inc. Recombinant human c1 esterase inhibitor and uses thereof
AU2017305856B2 (en) 2016-08-05 2024-09-12 Csl Behring Gmbh Pharmaceutical formulations of C1 esterase inhibitor
AU2017316513A1 (en) * 2016-08-23 2019-03-28 Csl Behring Gmbh Method of preventing acute attacks of hereditary angioedema associated with C1 esterase inhibitor deficiency
BR112019023737A2 (pt) * 2017-05-16 2020-05-26 Octapharma Ag Preparação de inibidor de c1-esterase (c1-inh), kit que consiste em um primeiro receptáculo contendo a preparação de c1-inh, kit que consiste em uma seringa pré-cheia com a preparação de c1-inh, kit que consiste em um dispositivo adequado para aplicação subcutânea, tal como um injetor no corpo e uso de histidina para aumentar a biodisponibilidade de c1-inh administrado por via subcutânea
PL3758739T3 (pl) 2018-02-28 2024-09-16 Pharming Intellectual Property B.V. Leczenie i zapobieganie stanowi przedrzucawkowemu
WO2019166572A1 (en) 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
WO2019245039A1 (ja) 2018-06-22 2019-12-26 株式会社Ｊｕｎｔｅｎ Ｂｉｏ 感染性免疫寛容を惹起するための組成物
KR20210024048A (ko) 2018-06-22 2021-03-04 가부시키가이샤 준텐 바이오 복합 상태를 갖는 세포 혼합물을 이용한, 면역 관용을 유도하는 항체 및 유도된 림프구, 또한 유도된 림프구를 이용하는 세포 치료제 및 치료법
AU2019288635A1 (en) 2018-06-22 2021-01-21 Junten Bio Co., Ltd. Antibody inducing immune tolerance, induced lymphocyte, and cell therapy agent therapeutic method using induced lymphocyte
CN114786724A (zh) * 2019-12-16 2022-07-22 尼普洛株式会社 防聚集剂以及使用该防聚集剂的药物组合物和医疗用设备
EP3895726A1 (en) 2020-04-17 2021-10-20 Pharming Intellectual Property BV Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress
CN117120076A (zh) * 2021-01-27 2023-11-24 斯帕克治疗公司 用于治疗遗传性血管性水肿的组合物和方法
JP2024525084A (ja) 2021-07-09 2024-07-09 ファーミング・インテレクチュアル・プロパティー・ビー．ブイ． Ｃ１エステラーゼ阻害剤によるウイルス感染関連症状の治療
KR20230046146A (ko) 2021-09-29 2023-04-05 주식회사 엘지에너지솔루션 배터리 제어 시스템 및 방법
WO2025090843A1 (en) * 2023-10-27 2025-05-01 Kansas State University Research Foundation Small-molecule inhibitors of c1s protease and classical complement pathway
CN119823254B (zh) * 2025-03-14 2025-06-03 深圳市卫光生物制品股份有限公司 一种c1酯酶抑制剂重组变体及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030140358A1 (en) 2000-01-31 2003-07-24 Nuijens Johannes Henricus C1 Inhibitor produced in the milk of transgenic mammals

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304482A (en) 1989-03-06 1994-04-19 The Board Of Regents Of The University Of Texas System Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors
WO1992022320A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. C1 inhibitor variants and treating inflammatory response with c1 inhibitor
JP4077030B2 (ja) * 1993-09-01 2008-04-16 ステイヒテイング・セントラール・ラボラトリウム・バン・デ・ブレドトランスフシーデイーンスト・バン・ヘト・ネーデルランドセ・ロデ・クルイス 急性心筋梗塞中の心筋傷害の低減方法
JP2000507204A (ja) 1995-12-18 2000-06-13 ステイヒテイング・サンキン・ブロードボールジーニング Ｃ１―インヒビターの補体及び血液凝固阻害特性の強化
AT409336B (de) 1999-12-22 2002-07-25 Baxter Ag Verfahren zur herstellung einer c1-esterase-inhibitor (c1-inh)-hältigen zusammensetzung
ES2299473T3 (es) 2000-01-31 2008-06-01 Pharming Intellectual Property B.V. Inhibidor de c1 humano producido en la leche de mamiferos transgenicos.
AU2002213441B2 (en) 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
DE10112617A1 (de) 2001-03-14 2002-10-02 Aventis Behring Gmbh Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren
WO2004034971A2 (en) 2002-09-25 2004-04-29 The Center For Blood Research, Inc. Methods for treating and preventing sepsis using modified c1 inhibitor or fragments thereof
WO2004110356A2 (en) 2003-05-15 2004-12-23 Cbr Institute For Biomedical Research, Inc. Methods for modulating cell-to-cell adhesion using an agonist of c1inh-type protein activity
EP1626736B1 (en) 2003-05-16 2020-09-16 Pharming Intellectual Property B.V. C1 inhibitor with short half-life for transient treatment
US20060233776A1 (en) 2003-08-19 2006-10-19 Norbert Heimburger C1-inh as a drug for treating viruses pathogenic to humans
US8501705B2 (en) 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
EP1893227A2 (en) 2005-06-06 2008-03-05 Girish J. Kotwal Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury
EP2433642B1 (en) 2005-10-21 2016-12-07 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
CN101365478B (zh) * 2005-12-21 2016-06-22 法明知识产权股份有限公司 C1抑制剂在预防缺血-再灌注损伤中的应用
AU2006327989B2 (en) 2005-12-21 2012-06-07 Pharming Intellectual Property Bv Use of C1 inhibitor for the prevention of ischemia-reperfusion injury
US7837992B2 (en) 2006-06-22 2010-11-23 Beth Israel Deaconess Medical Center C-1 inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis
EP2526962B1 (en) 2007-02-12 2019-08-14 CSL Behring GmbH Therapeutic application of Kazal-type serine protease inhibitors
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
TWI543768B (zh) 2007-11-30 2016-08-01 艾伯維生物技術有限責任公司 蛋白質調配物及製造其之方法
US20100143325A1 (en) 2008-12-09 2010-06-10 Vascular Laboratory, Inc. Composition And Methods Involving Thrombolytic Agents
JP5871798B2 (ja) 2009-07-02 2016-03-01 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 肝再生を刺激する方法
CN102781471B (zh) 2009-10-16 2016-10-12 奥默罗斯公司 通过抑制masp-2依赖性补体活化治疗弥散性血管内凝血的方法
CA2791841C (en) 2010-03-05 2023-01-03 Rigshospitalet Chimeric inhibitor molecules of complement activation
WO2011116291A1 (en) * 2010-03-18 2011-09-22 Thrombolytic Science International Production of human c1 inhibitor in human cells
WO2013013017A2 (en) * 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics
DK2758076T3 (en) 2011-09-24 2019-04-01 Csl Behring Gmbh COMBINATION THERAPY USING IMMUNOGLOBULIN AND C1 INHIBITOR
DK2793935T3 (en) * 2011-12-22 2016-09-05 Csl Behring Gmbh Use of C1 inhibitor in the treatment of secondary edema in the central nervous system.
WO2013138730A1 (en) 2012-03-16 2013-09-19 Enzon Pharmaceuticals, Inc. Polymeric conjugates of c1-inhibitors
HK1214652A1 (zh) 2013-03-13 2016-07-29 克里蒂科斯有限责任公司 用於检测胰腺癌的方法和组合物
BR112015023207A8 (pt) * 2013-03-15 2018-01-23 Shire Viropharma Inc composições de ci-inh e métodos para prevenção e tratamento de desordens associadas à deficiência de inibidor de c1 esterase.
JP6889626B2 (ja) * 2017-06-29 2021-06-18 トキコシステムソリューションズ株式会社 燃料供給システム
JP6935245B2 (ja) * 2017-06-29 2021-09-15 大和ハウス工業株式会社 収容ラック

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030140358A1 (en) 2000-01-31 2003-07-24 Nuijens Johannes Henricus C1 Inhibitor produced in the milk of transgenic mammals

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ClinicalTrials.gov_NCT00748202 (Last update posted: 2011.1.19.)*
Richard G. Gower, 등, WAO Journal 2011, 4, S9-S21*

Also Published As

Publication number Publication date
AU2020203183A1 (en) 2020-06-04
HRP20190270T1 (hr) 2019-04-05
US20190160158A1 (en) 2019-05-30
US10080788B2 (en) 2018-09-25
JP2019073546A (ja) 2019-05-16
EP2968434A2 (en) 2016-01-20
JP2016516073A (ja) 2016-06-02
SI2968434T1 (sl) 2017-11-30
DK2968434T3 (en) 2017-09-11
ME02865B (me) 2018-04-20
HUE036224T2 (hu) 2018-06-28
US20170224788A1 (en) 2017-08-10
NZ751555A (en) 2021-07-30
JP6473535B2 (ja) 2019-02-20
PL3290046T3 (pl) 2019-05-31
CA2904543C (en) 2019-10-08
EP3508213A1 (en) 2019-07-10
HUE041837T2 (hu) 2019-05-28
MX2020004724A (es) 2022-01-18
JP6473536B2 (ja) 2019-02-20
SG11201507616VA (en) 2015-10-29
GB201519921D0 (en) 2015-12-23
JP2018119000A (ja) 2018-08-02
WO2014145519A2 (en) 2014-09-18
US20190160157A1 (en) 2019-05-30
IL241549B (en) 2020-08-31
HRP20171269T1 (hr) 2017-11-03
EA201591278A1 (ru) 2016-03-31
SI3290046T1 (sl) 2019-04-30
EP2968434A4 (en) 2016-03-02
MX2015011281A (es) 2016-03-03
EP2968434B1 (en) 2017-06-28
ME03326B (me) 2019-10-20
AU2018229558B2 (en) 2020-03-05
KR20220070049A (ko) 2022-05-27
ES2639833T3 (es) 2017-10-30
JP6877470B2 (ja) 2021-05-26
IL276153A (en) 2020-09-30
MX2021011946A (es) 2021-11-17
PL2968434T3 (pl) 2018-01-31
JP2018119002A (ja) 2018-08-02
JP6877472B2 (ja) 2021-05-26
KR20210129267A (ko) 2021-10-27
MX373965B (es) 2020-07-13
KR20150135242A (ko) 2015-12-02
CY1121653T1 (el) 2020-07-31
AU2018229558A1 (en) 2018-10-04
ZA201806793B (en) 2020-01-29
LT2968434T (lt) 2017-09-25
JP6422520B2 (ja) 2018-11-14
LT3290046T (lt) 2019-03-12
MX389449B (es) 2025-03-20
JP6877471B2 (ja) 2021-05-26
US11534482B2 (en) 2022-12-27
IL276153B (en) 2022-06-01
SMT201700415T1 (it) 2017-11-15
EP3290046B1 (en) 2019-01-02
AU2014232912A1 (en) 2015-09-03
JP2021088599A (ja) 2021-06-10
PT3290046T (pt) 2019-02-18
RS58351B1 (sr) 2019-03-29
US10105423B2 (en) 2018-10-23
PT2968434T (pt) 2017-09-18
CA3054718A1 (en) 2014-09-18
DK3290046T3 (en) 2019-03-18
US20180153972A1 (en) 2018-06-07
GB2530921B (en) 2017-09-20
TR201900319T4 (tr) 2019-02-21
JP2019073545A (ja) 2019-05-16
CN111529708A (zh) 2020-08-14
CN105517559A (zh) 2016-04-20
CY1119419T1 (el) 2018-03-07
JP6473534B2 (ja) 2019-02-20
AU2020203183B2 (en) 2022-06-02
ES2713004T3 (es) 2019-05-17
HK1250912B (en) 2020-01-10
KR102579789B1 (ko) 2023-09-15
WO2014145519A3 (en) 2014-12-31
JP2018119001A (ja) 2018-08-02
BR112015023207A8 (pt) 2018-01-23
ZA201706929B (en) 2019-05-29
US20180110844A1 (en) 2018-04-26
NZ710730A (en) 2021-07-30
US10130690B2 (en) 2018-11-20
EP3290046A1 (en) 2018-03-07
JP6184581B2 (ja) 2017-08-23
SG10201707598QA (en) 2017-10-30
US20160015795A1 (en) 2016-01-21
BR112015023207A2 (pt) 2017-11-21
HK1220403A1 (en) 2017-05-05
US11364288B2 (en) 2022-06-21
CA2904543A1 (en) 2014-09-18
US20200261556A1 (en) 2020-08-20
ZA201507604B (en) 2018-05-30
SMT201900141T1 (it) 2019-05-10
RS56285B1 (sr) 2017-12-29
US10201595B2 (en) 2019-02-12
US20180110843A1 (en) 2018-04-26
US20180085441A1 (en) 2018-03-29
KR20210021146A (ko) 2021-02-24
JP2017105847A (ja) 2017-06-15
DE202014011208U1 (de) 2018-08-23
GB2530921A (en) 2016-04-06
US9616111B2 (en) 2017-04-11
JP2019073544A (ja) 2019-05-16

Similar Documents

Publication Publication Date Title
KR102430453B1 (ko) C1 에스터라제 억제제 결핍과 관련된 장애의 예방 및 치료를 위한 c1-inh 조성물 및 방법
HK40036345A (en) C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficiency
HK1220403B (en) C1-inh compositions for use in the prevention and treatment of hereditary angioedema (hae).

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4